Impedimed Ltd (ASX: IPD) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

ImpediMed Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $171.54 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 1.49 billion
Earnings per share -0.021
Dividend per share N/A
Year To Date Return -8.00%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

IPD ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Impedimed Ltd

Impedimed Ltd together with its subsidiaries operates in the medical devices space. The company is based in Australia and operates globally, and it generates most of its revenue in North America. It is engaged in developing, manufacturing,and distributing noninvasive medical devices. The company offers products that are typically used to assess and monitor lymphedema and heart failure, as well as to measure the tissue composition and fluid status of the patients. The company also offers a cloud-based digital platform (branded as SOZO) to manage patient data.

IPD Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
11 Jun 2021 $0.12 $0.00 0.00% 2,134,055 $0.12 $0.12 $0.11
10 Jun 2021 $0.12 $0.00 0.00% 988,377 $0.12 $0.12 $0.11
09 Jun 2021 $0.12 $0.00 0.00% 1,976,291 $0.12 $0.12 $0.11
08 Jun 2021 $0.12 $0.00 0.00% 460,576 $0.12 $0.12 $0.12
07 Jun 2021 $0.12 $-0.01 -8.00% 1,653,638 $0.13 $0.13 $0.12
04 Jun 2021 $0.13 $0.00 0.00% 1,133,141 $0.13 $0.13 $0.12
03 Jun 2021 $0.13 $0.01 8.33% 953,131 $0.13 $0.13 $0.12
02 Jun 2021 $0.12 $-0.01 -8.00% 661,313 $0.12 $0.13 $0.12
01 Jun 2021 $0.13 $-0.01 -7.69% 1,579,495 $0.12 $0.13 $0.12
31 May 2021 $0.13 $0.00 0.00% 2,111,424 $0.13 $0.14 $0.13
28 May 2021 $0.13 $0.01 8.00% 2,636,351 $0.12 $0.13 $0.12
27 May 2021 $0.13 $0.00 0.00% 2,058,910 $0.13 $0.13 $0.12
26 May 2021 $0.13 $0.00 0.00% 5,152,945 $0.13 $0.13 $0.12
25 May 2021 $0.13 $0.00 0.00% 1,292,916 $0.13 $0.13 $0.12
24 May 2021 $0.13 $0.00 0.00% 1,245,759 $0.13 $0.13 $0.13
21 May 2021 $0.13 $0.01 8.33% 2,480,958 $0.12 $0.13 $0.12
20 May 2021 $0.12 $0.00 0.00% 1,831,395 $0.12 $0.13 $0.12
19 May 2021 $0.12 $-0.01 -8.00% 1,198,785 $0.13 $0.13 $0.12
18 May 2021 $0.13 $0.01 8.33% 6,730,682 $0.12 $0.14 $0.12

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
07 Apr 2021 Judith Downes Exercise 143 $5,369
Exercise of options. As per announcement on 08/04/2021.
07 Apr 2021 Judith Downes Buy 299 $11,236
Exercise of options.
07 Apr 2021 Judith Downes Buy 143 $5,369
Exercise of options.
07 Apr 2021 Judith Downes Exercise 299 $11,236
Exercise of options. As per announcement on 08/04/2021.
01 Apr 2021 Judith Downes Issued 170 $18,750
Director remuneration.
01 Apr 2021 Judith Downes Issued 170 $18,750
Director remuneration.
01 Apr 2021 Richard Carreon Issued 162 $17,843
Director remuneration.
01 Apr 2021 Scott Ward Issued 342 $37,640
Director remuneration.
01 Apr 2021 Robert (Bob) Graham Issued 153 $16,874
Director remuneration.
01 Apr 2021 Amit Patel Issued 200 $22,098
Director remuneration.
01 Apr 2021 Donald (Don) Williams Issued 245 $27,008
Director remuneration.
04 Jan 2021 Amit Patel Issued 122 $16,342
Director remuneration.
04 Jan 2021 Robert (Bob) Graham Issued 95 $12,656
Director remuneration.
04 Jan 2021 Scott Ward Issued 209 $27,836
Director remuneration.
04 Jan 2021 Richard Carreon Issued 139 $18,542
Director remuneration.
04 Jan 2021 Judith Downes Issued 105 $14,062
Director remuneration.
04 Jan 2021 Donald (Don) Williams Issued 150 $19,974
Director remuneration.
04 Jan 2021 David Anderson Issued 122 $16,342
Director remuneration.
16 Nov 2020 Richard Carreon Issued 631 $60,576
Conversion of securities. As per announcement on 16/11/2020.
There is no transaction reported for conversion of rights.
10 Nov 2020 Richard Carreon Issued 7 $673,400
Issue of securities. 10,624,871 - Performance Rights
10 Nov 2020 Richard Carreon Issued 262 $20,718
Director remuneration.
10 Nov 2020 Richard Carreon Issued 6 $560,469
Issue of options.
07 Oct 2020 Robert (Bob) Graham Buy 269 $10,113
Exercise of options.
07 Oct 2020 Robert (Bob) Graham Exercise 269 $10,113
Exercise of options.
01 Oct 2020 Robert (Bob) Graham Issued 188 $12,656
Director remuneration.
01 Oct 2020 Amit Patel Issued 263 $17,666
Director remuneration.
01 Oct 2020 Donald (Don) Williams Issued 322 $21,591
Director remuneration.
01 Oct 2020 Scott Ward Issued 449 $30,091
Director remuneration.
01 Oct 2020 Judith Downes Issued 209 $14,062
Director remuneration.
01 Oct 2020 David Anderson Issued 234 $15,703
Director remuneration.
01 Jul 2020 Judith Downes Issued 213 $14,062
Director remuneration.
01 Jul 2020 Richard Carreon Issued 349 $23,090
Director remuneration.
01 Jul 2020 Scott Ward Issued 479 $31,618
Director remuneration.
01 Jul 2020 David Anderson Issued 155 $10,290
Director remuneration.
01 Jul 2020 Donald (Don) Williams Issued 343 $22,687
Director remuneration.
01 Jul 2020 Robert (Bob) Graham Issued 191 $12,656
Director remuneration.
01 Jul 2020 Amit Patel Issued 281 $18,562
Director remuneration.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Ms Judith Susan Downes Non-Executive Director Apr 2017
Ms Downes brings over 25 years of accounting and senior management expertise to the Board with a strong focus on financial management and audit and risk management, with large ASX listed companies. During her executive career, she held the roles of CFO at Alumina Limited (ASX: AWC) and as CFO/COO of Institutional Division, ANZ Banking Group Limited (ASX: ANZ). Judith currently serves as Board Chairman of Bank Australia Limited. Judith has experience in corporate governance, debt and equity raisings, financial reporting and Australian listing rules. Ms Downes is chair of Risk Management Committee. She is also director of CleanTeQ Holdings Limited.
Mr Richard Carreon Chief Executive OfficerManaging Director Jul 2012
Mr Carreon has more than 30 years of experience in management, sales and marketing, spanning the consumer products and medical technology industries. Rick has more than a decade of executive experience working for Medtronic, a leading global manufacturer of cutting-edge medical devices, and therapies. His roles at Medtronic included Vice President, US Cardiovascular Commercial Operations; Vice President of Sales - Structural Heart; Vice President of Sales and Marketing Medtronic Gastroenterology and Urology; and Vice President of Sales - The Americas. Rick has a sales background, marketing strategy and execution experience, and a proven track record of success. He is renowned for building start-up and high-growth ventures, turning around strategic business units, penetrating new markets and delivering strong and sustainable profits, revenues and market share value. At Medtronic, Rick led strategic direction and tactical planning for several sales organisations within Medtronic's $1.1B Cardiovascular Sector. Rick was handpicked to lead the start-up of Medtronic Gastroenterology and Urology, a high-risk business venture, growing revenues threefold, and building that venture into the fastest growing business in Medtronic.
Mr Scott R Ward Non-Executive DirectorNon-Executive Chairman Jul 2013
Mr Ward is the Chairman of the Board, President and CEO of Cardiovascular Systems Inc. Scott has over 35 years of experience in the healthcare industry, including nearly 30 years at Medtronic, Inc. He was the Senior Vice President and President of the CardioVascular business of Medtronic Inc., responsible for all worldwide operations of the CardioVascular Business including the Coronary, Peripheral, Endovascular, Structural Heart Disease and Revascularization and Surgical Therapies businesses. Previously, Scott served as Senior Vice President and President of Medtronic Neurological and Diabetes, with responsibility for the global Neurological, Neurologic Technologies, Diabetes, Gastroenterology and Urology businesses; Vice President and General Manager of the Medtronic Drug Delivery Business; and Director of Medtronic NeuroVentures. Scott is also the Founder of Raymond Holdings, LLC a firm with activities in venture capital, strategy and transactional advisory services. Scott's experience in the healthcare industry, including his leadership experience of public medical device companies and his prior service on the boards of public medical device companies, make him a contributor to the Board.
Professor Robert (Bob) Graham Non-Executive Director Nov 2017
Dr Graham received his medical training at the University of New South Wales, Australia, where he is now the Des Renford Professor of Medicine, (UNSW). He was been the inaugural Executive Director, Victor Chang Cardiac Research Institute (VCCRI), Sydney, Australia, from 1994 - 2020, and continues there as Head, Molecular Cardiology and Biophysics Division, VCCRI, and Des Renford Professor of Medicine, University of NSW. Bob returned to Australia in 1994 after 17 years working in the US at the University of Texas Southwestern Medical School, Dallas; the Massachusetts General Hospital, Harvard Medical School; the Massachusetts Institute of Technology, and the Cleveland Clinic Foundation and Case Western Reserve University School of Medicine.
Mr Amit Patel Non-Executive Director Mar 2017
Mr Patel is a Co-Founder and CEO of Murata Vios (formerly Vios Medical), which has created an FDA-cleared patient management platform that integrates IoT-based monitoring, remote care services, and big data analytics to alleviate gaps in patient vigilance across in-hospital and home environments. Vios is currently commercialising its monitoring and services solution across major hospital systems in the US and India. Vios Medical was acquired by Murata Manufacturing in October of 2017. Prior to founding Vios, Amit was with HeartFlow where he created a joint go-to-market strategy with GE Healthcare's imaging division, managed the DeFACTO clinical study across multiple UK sites, and developed a health economic story for the NHS. Prior to HeartFlow, Amit was with Medtronic's Corporate Development group and was responsible for acquisitions, minority investments, and joint ventures spanning existing businesses and strategic whitespace areas. Amit is also member of Risk Management Committee.
Mr Donald (Don) Williams Non-Executive Director Mar 2017
Mr Williams has more than 35 years in leadership roles as a Certified Public Accountant (CPA) and an accredited public company director, serving the life science, biotech, and medical device industries. Don has experience assisting companies and management teams with initial public offerings, complex business challenges and analysis of financial reporting matters. His breadth of experience includes a diverse set of growing domestic and international companies including venture financings, public equity offerings, public debt offerings, mergers and acquisitions, and interaction with the US Securities and Exchange Commission and Public Company Accounting Oversight Board. While at both Ernst & Young and Grant Thornton, Don was focused on the Life Sciences Industry. For over 15 years, he directed Ernst & Young's Venture Capital and Emerging Growth Markets in the Southeast Market and in the Pacific Southwest Market. During his seven years at Grant Thornton he was the National Leader of the United States Life Sciences Industry. His oversight of the National Life Sciences Industry included setting strategy, establishing the sales and marketing plan and oversight of industry operations. He is also member of Risk Management Committee and is also director of Akari Therapeutics, Alphatec Holdings, Forte Biosciences and former director of Adhera Therapeutics.
Mr David W Anderson Non-Executive Director May 2020
Mr Anderson currently serves as President and CEO of HealthNow Systems Inc, operating as Blue Cross Blue Shield health plans in New York State. HealthNow operates as a licensee of the Blue Cross Blue Shield Association, which in total, provides health care services to 1 in every 3 Americans across all 50 states and US territories and is accepted at over 90% of US doctors, hospitals and other health care providers. David is a experienced and respected US health care industry executive who serves on the board of the National Institute of Healthcare Management, Blue Cross Blue Shield Association board of Directors, the board of the New York State Business Council and the New York State Insurance Advisory Committee as appointed by the Commissioner of the Department of Financial Services. Additionally, David serves as an advisor and speaker for Modern Healthcare's CEO Power Panel and the Aspen Institute. Prior to his role at BCBS, Mr. Anderson was CEO of United Healthcare's Southern California Health Plan. Mr Anderson is a native of Fort Wayne, Indiana.
Ms Leanne Ralph Company Secretary Jan 2015
-
Shashi Tripathi Chief Technology Officer
-
Leanne Ralph Company Secretary
-
Catherine Kingsford Senior Vice President Medical Affairs
-
David Adams Senior Vice President Operations and Strategic Planning
-
Dennis Schlaht Senior Vice President R&D and Technology
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited 94,116,697 9.09%
National Nominees Limited 83,484,732 8.07%
Citicorp Nominees Pty Limited 48,516,192 4.69%
HSBC Custody Nominees (Australia) Limited A/C 2 40,372,280 3.90%
J P Morgan Nominees Australia Pty Limited 26,344,467 2.55%
CS Third Nominees Pty Limited 24,212,886 2.34%
Mr Gregory Wayne Brown 20,000,000 1.93%
Bnp Paribas Nominees Pty Ltd 19,812,718 1.91%
HSBC Custody Nominees (Australia) Limitedgsi Eda 14,999,999 1.45%
Sunlora Pty Ltd 14,000,000 1.35%
Mr Gregory Wayne Brown & Mrs Stefanie Brown 13,080,000 1.26%
Mba Investments Pty Ltd 11,297,134 1.09%
Mr Stephen Edward Mahnken & Mrs Dior Leone Mahnken 10,000,000 0.97%
Pakasoluto Pty Limited 9,153,298 0.88%
Apex Investment Management Pty Limited 9,095,288 0.88%
Bnp Paribas Nominees Pty Ltd I 8,708,075 0.84%
Sandhurst Trustees Ltd 8,168,695 0.79%
Pasagean Pty Limited 7,280,002 0.70%
Moore Family Nominee Pty Ltd 6,600,000 0.64%
Equitas Nominees Pty Limited 5,853,137 0.57%

Profile

since

Note